Vascular Biogenics Ltd.

Tel Hashomer Medical Research Infrastructure and Services Ltd.

Nikken Sohonsha Corporation

Syntex (u.s.a.) Inc.

Memorial Sloan Kettering Cancer Center

Dror Harats

Michel Sadelain

Eyal Breitbart

Jacob George

Gideon Halperin

Shoshana Greenberger

Eti Kovalevski-Ishai

Niva Yacov

Michael R Peled

Itzhak Mendel

Michael Belkin

Richard N Kolesnick

Aviv Shaish

Livnat Bangio

Nira Bloom

Ygal Rotenstreich

Paula Nanette Belloni

Zvi Fuks

Hiroki Kurihara

Charles Elliott Sigal

Branka Stancevic

Nira Varda-bloom

The invention is a method for treating psoriasis in a subject suffering from psoriasis. The method includes orally administering to the subject a pharmaceutically-effective amount of crudepowder.

Method for treating psoriasis

Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crudepowder. Also provided is a method for improving night vision and/or rod derived visual field in a subject suffering from a retinal disease including administering to the subject a pharmaceutically effective amount of crudepowder. A pharmaceutical composition for improving day vision and/or visual field in a subject suffering from a retinal disease including crudepowder is also provided.

Method of treating retinitis pigmentosa

A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.

Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy

An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.

Promoters exhibiting endothelial cell specificity and methods of using same

Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.

Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.

Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis

Methods of treating ophthalmic disorders

Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.

Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders

Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy

A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating to a subject an effective amount of crudepowder, optionally together with an activator of nuclear receptors.

[object Object]

Growing community of inventors

Ramat Gan, Israel

Dror Harats